Karen Jean Ferrante - 01 Jul 2025 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Role: Director
Signature: /s/ Evan D. Kearns, Attorney-in-Fact
Issuer symbol: COGT
Transactions as of: 01 Jul 2025
Net transactions value: $0
Form type: 4
Filing time: 02 Jul 2025, 16:15:43 UTC
Previous filing: 05 Jun 2025
Next filing: 03 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ferrante Karen Jean	Director	C/O COGENT BIOSCIENCES, INC., 275 WYMAN STREET, 3RD FLOOR, WALTHAM	/s/ Evan D. Kearns, Attorney-in-Fact	02 Jul 2025	0001598502

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	COGT	Stock Option (Right to Buy)	Award	$0	+3,314		$0.000000	3,314	01 Jul 2025	Common Stock	3,314	$7.22	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Content

The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.